Argent Biopharma (ASX:RGT)
ASX announcement history & article coverage
Transparent by design.
Announcments by Argent Biopharma (ASX:RGT) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification of cessation of securities - RGT
Appendix 4E and 2026 Annual Report
Argent BioPharma reports $7.7M loss, secures global CannEpil licensing deal and $11M financing facility
Appendix 4G and Corporate Governance Statement
FDA-CVM Establish INAD File for CannEpil Veterinary Program
FDA Establishes INAD File for Argent BioPharma's CannEpil Veterinary Program
Proposed issue of securities - RGT
$250,000 in Funding Received under Financing Facility
US Veterinary Development Programme for CannEpil Commences
Argent BioPharma launches U.S. veterinary development program for CannEpil®
Notification of cessation of securities - RGT
CannEpil Global Licence Expands into Veterinary Healthcare
Argent BioPharma Expands CannEpil® License to Veterinary Market with New Royalty Stream
Quarterly Activities/Appendix 4C Cash Flow Report
Argent BioPharma secures global CannEpil license deal eliminating US$5.5m debt, advances veterinary asset acquisition and clinical progress
Notification of cessation of securities - RGT
s708A(12C)(e) Cleansing Notice
Notification regarding unquoted securities - RGT
Proposed issue of securities - RGT
$350,000 in Funding Received under Financing Facility
Application for quotation of securities - RGT
RGT Executes Global CannEpil Licensing Deal for US$5.5M
Argent BioPharma licenses CannEpil® globally to Splash Beverage for US$5.5M upfront and 15% royalties
